Arkolith/Insider Trading/RVNC/Form 4

Foley Mark J

CEO, DirectorRevance Therapeutics, Inc. (RVNC) · full profile →Form 4 · filed Aug 15, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 11, 2023Tax withholding(F)48K$18.91$909K914K
Aug 11, 2023Grant(A)122K—$0963K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001479290-23-000096) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML